MEK Inhibitor FCN-159 To Treat Advanced Melanoma With NRAS-aberrant (Ia) and NRAS-mutant (Ib)or NF1-mutant(1b)

Exclusion Criteria

• •1. Radiotherapy, major surgery, mono-clone antibody targeted therapy, immunotherapy or other treatment within 4 weeks prior to enrollment.
• •2. Chemotherapy and small molecule targeted therapy within 2 weeks of enrollment.
• •3. Participated in other clinical trials within 4 weeks prior to enrollment or 5 T1/2;
• •4. Previous usage of MEK inhibitor;
• •5. Uncontrolled central nervous system metastasis or injury.
• •6. Unrecovered \>grade 2 AE caused by previous anti-tumor therapy;
• •7. Strong inhibitors/inducers of CYP3A4, CYP2C8 or CYP2C9 within 14 days prior to the start of dosing.
• •8. Taking drugs that prolong QTc interval;
• •9. Dysphagia, or active digestive system disease, or malabsorption syndrome, or other conditions affecting FCN-159 absorption.
• •10. Previous or current retinal vein stenosis, retinal detachment, central retinal vein occlusion, glaucoma.
• •11. Interstitial pneumonia, including clinically significant radiationpneumonitis.
• •12. Insufficient cardiac function or disease;
• •13. Pregnant or lactating woman.
• •14. Known to be allergic to any excipients of FCN-159.
• •15. Clinically active infections;
• •16. Significant active disease that in the investigator's opinion would adversely impact on his/her participation in the study.